Childrens Specialty Group — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$7,522	2
2024	Research	$166,430	6
2023	Research	$329,338	2
2022	Research	$9,964	4
2021	Research	$23,060	3

Breakdown

Who paid Research payments · program years 2021–2025

Novartis Pharmaceuticals Corporation $455,789 6 payments
Amgen Inc. $61,925 10 payments
Neurelis, Inc. $18,600 1 payment

Studies the money was for Research payments · program years 2021–2025

A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Patients Type 2 Spinal Muscular Atrophy (SMA) Who Are 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory $298,534 2 payments
Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to 12 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza) or Risdiplam (Evrysdi) $149,733 2 payments
Phase P3 Pediatric Study EM $29,208 2 payments
Ph3 Pediatric CM Study $23,203 4 payments
An Open-Label, Single-Dose, Pharmacokinetics Study of Valtoco With Open-Label Safety Period in Pediatric Subjects With Epilepsy $18,600 1 payment
Phase Iiib, Open-Label, Single-Arm, Multi-Center Study to Evaluate the Safety, Tolerability and Efficacy of Oav101 Administered Intrathecally (1.2 X 10^14 Vector Genomes) to Participants 2 to 12 Years of Age With Spinal Muscular Atrophy (Sma) Who Have Dis $5,500 1 payment
Phase P3 Pediatric Study (EM) $5,054 2 payments
Ph3 Pediatric CM Study. $2,230 1 payment
Phase P3 Pediatric Study (EM). $2,230 1 payment
A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 $2,022 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.